Epizyme, Inc. to Present at Upcoming Events in October

CAMBRIDGE, Mass.--()--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming events in October:

“Pre-Clinical Evaluation of EZH2 Inhibitors in Models of Human Synovial Sarcoma.”

  • Leerink Partners Rare Disease Roundtable at Le Parker Meridien Hotel in New York on Wednesday, October 1. Epizyme CEO Robert Gould, Ph.D., will participate in a fireside chat presentation at 9:15 a.m. ET. A live webcast will be available by visiting the Investor Center on the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company’s website for 60 days after the conference.
  • Xconomy Boston Life Science Disruptors Event at the Novartis Institutes for Biomedical Research in Cambridge, Mass., on Wednesday, October 8 at 6:00 p.m. ET. Dr. Gould will participate in a panel discussion on successful recent biotechnology initial public offerings (IPOs).
  • Annual Meeting of the Connective Tissue Oncology Society at the Intercontinental Hotel in Berlin, Germany on Friday, October 17. Epizyme Director of Biological Sciences Heike Keilhack, Ph.D., will present a poster titled “Pre-Clinical Evaluation of EZH2 Inhibitors in Models of Human Synovial Sarcoma.” The poster will be available in the Media Center on the Epizyme website at www.epizyme.com after the presentation.

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Contacts

Media/Investors:
Epizyme, Inc.
Manisha Pai, 617-229-7560
mpai@epizyme.com

Epizyme, Inc.